BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 28637434)

  • 1. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
    Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
    Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.
    Tsunedomi R; Hazama S; Fujita Y; Okayama N; Kanekiyo S; Inoue Y; Yoshino S; Yamasaki T; Suehiro Y; Oba K; Mishima H; Sakamoto J; Hamamoto Y; Oka M
    Int J Oncol; 2014 Oct; 45(4):1381-90. PubMed ID: 25175642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
    Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
    Martinez-Balibrea E; Abad A; Martínez-Cardús A; Ginés A; Valladares M; Navarro M; Aranda E; Marcuello E; Benavides M; Massutí B; Carrato A; Layos L; Manzano JL; Moreno V
    Br J Cancer; 2010 Aug; 103(4):581-9. PubMed ID: 20628391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients.
    Li GY; Duan JF; Li WJ; Liu T
    J Cancer Res Ther; 2016; 12(2):782-6. PubMed ID: 27461651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
    J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
    J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
    Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
    Yu Q; Zhang T; Xie C; Qiu H; Liu B; Huang L; Peng P; Feng J; Chen J; Zang A; Yuan X
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):87-98. PubMed ID: 29728798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 17. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
    Inoue K; Sonobe M; Kawamura Y; Etoh T; Takagi M; Matsumura T; Kikuyama M; Kimura M; Minami S; Utsuki H; Yamazaki T; Suzuki T; Tsuji D; Hayashi H; Itoh K
    Tohoku J Exp Med; 2013 Feb; 229(2):107-14. PubMed ID: 23303296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
    Lévesque E; Bélanger AS; Harvey M; Couture F; Jonker D; Innocenti F; Cecchin E; Toffoli G; Guillemette C
    J Pharmacol Exp Ther; 2013 Apr; 345(1):95-101. PubMed ID: 23386248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
    Li J; Yu Q; Fu S; Xu M; Zhang T; Xie C; Feng J; Chen J; Zang A; Cai Y; Fu Q; Liu S; Zhang M; Hong Q; Huang L; Yuan X
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1621-8. PubMed ID: 27160286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.